Targeting SmCB1: Perspectives and Insights to Design Antischistosomal Drugs


如何引用文章

全文:

详细

Neglected tropical diseases (NTDs) are prevalent in tropical and subtropical countries, and schistosomiasis is among the most relevant diseases worldwide. In addition, one of the two biggest problems in developing drugs against this disease is related to drug resistance, which promotes the demand to develop new drug candidates for this purpose. Thus, one of the drug targets most explored, Schistosoma mansoni Cathepsin B1 (SmCB1 or Sm31), provides new opportunities in drug development due to its essential functions for the parasite's survival. In this way, here, the latest developments in drug design studies targeting SmCB1 were approached, focusing on the most promising analogs of nitrile, vinyl sulphones, and peptidomimetics. Thus, it was shown that despite being a disease known since ancient times, it remains prevalent throughout the world, with high mortality rates. The therapeutic arsenal of antischistosomal drugs (ASD) consists only of praziquantel, which is widely used for this purpose and has several advantages, such as efficacy and safety. However, it has limitations, such as the impossibility of acting on the immature worm and exploring new targets to overcome these limitations. SmCB1 shows its potential as a cysteine protease with a catalytic triad consisting of Cys100, His270, and Asn290. Thus, design studies of new inhibitors focus on their catalytic mechanism for designing new analogs. In fact, nitrile and sulfonamide analogs show the most significant potential in drug development, showing that these chemical groups can be better exploited in drug discovery against schistosomiasis. We hope this manuscript guides the authors in searching for promising new antischistosomal drugs.

作者简介

Igor dos Santos Nascimento

Pharmacy Department,, Cesmac University Center

编辑信件的主要联系方式.
Email: info@benthamscience.net

Sonaly Albino

Laboratório de Desenvolvimento e Síntese de Fármacos, Departamento de Farmácia,, Universidade Estadual da Paraíba

Email: info@benthamscience.net

Karla da Silva Menezes

Laboratório de Desenvolvimento e Síntese de Fármacos, Departamento de Farmácia,, Universidade Estadual da Paraíba

Email: info@benthamscience.net

Misael de Azevedo Teotônio Cavalcanti

Laboratório de Desenvolvimento e Síntese de Fármacos, Departamento de Farmácia,, Universidade Estadual da Paraíba

Email: info@benthamscience.net

Mozaniel de Oliveira

, Coordination of Botany-Laboratory Adolpho Ducke, Avenida Perimetral, Museu Paraense Emílio Goeldi

Email: info@benthamscience.net

Suraj Mali

Department of Pharmaceutical Sciences and Technology, I, Institute of Chemical Technology

Email: info@benthamscience.net

Ricardo de Moura

Laboratório de Desenvolvimento e Síntese de Fármacos, Departamento de Farmácia, Universidade Estadual da Paraíba,

Email: info@benthamscience.net

参考

  1. Ferreira, L.L.G.; de Moraes, J.; Andricopulo, A.D. Approaches to advance drug discovery for neglected tropical diseases. Drug Discov. Today, 2022, 27(8), 2278-2287. doi: 10.1016/j.drudis.2022.04.004 PMID: 35398562
  2. Nascimento, I.J.S.; Santos-Júnior, P.F.S.; Aquino, T.M.; Araújo-Júnior, J.X.; Silva-Júnior, E.F. Insights on Dengue and Zika NS5 RNA-dependent RNA polymerase (RdRp) inhibitors. Eur. J. Med. Chem., 2021, 224, 113698. doi: 10.1016/j.ejmech.2021.113698 PMID: 34274831
  3. de Aquino, T.M.; França, P.H.B.; Rodrigues, É.E.E.S.; Nascimento, I.J.S.; Santos-Júnior, P.F.S.; Aquino, P.G.V.; Santos, M.S.; Queiroz, A.C.; Araújo, M.V.; Alexandre-Moreira, M.S.; Rodrigues, R.R.L.; Rodrigues, K.A.F.; Freitas, J.D.; Bricard, J.; Meneghetti, M.R.; Bourguignon, J.J.; Schmitt, M.; da Silva-Júnior, E.F.; de Araújo-Júnior, J.X. Synthesis, antileishmanial activity and in silico studies of aminoguanidine hydrazones (AGH) and thiosemicarbazones (TSC) against Leishmania chagasi Amastigotes. Med. Chem., 2022, 18(2), 151-169. doi: 10.2174/1573406417666210216154428 PMID: 33593264
  4. WHO ⋅ World Health Organization. 2020. Neglected tropical diseases. Available at: https://www.who.int/neglected_diseases/diseases/en/ Accessed on: 06 Jun. 2023.
  5. Ferreira, L.L.G.; Andricopulo, A.D. Drugs and vaccines in the 21st century for neglected diseases. Lancet Infect. Dis., 2019, 19(2), 125-127. doi: 10.1016/S1473-3099(19)30005-2 PMID: 30712832
  6. dos Santos Nascimento, I.J.; de Aquino, T.M.; da Silva-Júnior, E.F. Drug repurposing: A strategy for discovering inhibitors against emerging viral infections. Curr. Med. Chem., 2021, 28(15), 2887-2942. doi: 10.2174/1875533XMTA5rMDYp5 PMID: 32787752
  7. dos Santos Nascimento, I.J.; da Silva Rodrigues, É.E.; da Silva, M.F.; de Araújo-Júnior, J.X.; de Moura, R.O. Advances in computational methods to discover new NS2B-NS3 inhibitors useful against dengue and zika viruses. Curr. Top. Med. Chem., 2022, 22(29), 2435-2462. doi: 10.2174/1568026623666221122121330 PMID: 36415099
  8. da Conceição, J.R.; Lopes, C.P.G.; Ferreira, E.I.; Epiphanio, S.; Giarolla, J. Neglected tropical diseases and systemic racism especially in Brazil: from socio-economic aspects to the development of new drugs. Acta Trop., 2022, 235, 106654. doi: 10.1016/j.actatropica.2022.106654 PMID: 35988823
  9. McManus, D.P.; Bergquist, R.; Cai, P.; Ranasinghe, S.; Tebeje, B.M.; You, H. Schistosomiasis-from immunopathology to vaccines. Semin. Immunopathol., 2020, 42(3), 355-371. doi: 10.1007/s00281-020-00789-x PMID: 32076812
  10. José dos, S.N.I.; de Aquino, M.T.; da Silva Santos-Júnior, F.P.; de Araújo-Júnior, X.J.; da Silva-Júnior, F.E. Molecular modeling applied to design of cysteine protease inhibitors – a powerful tool for the identification of hit compounds against neglected tropical diseases. In: Frontiers in Computational Chemistry; , 2020; p. 63-110.
  11. Alzain, A.A.; Elbadwi, F.A. De novo design of cathepsin b1 inhibitors as potential anti-schistosomal agents using computational studies. Adv. Appl. Bioinform. Chem., 2022, 15, 29-41. doi: 10.2147/AABC.S361626 PMID: 35935393
  12. Mansour, N.R.; Paveley, R.; Gardner, J.M.F.; Bell, A.S.; Parkinson, T.; Bickle, Q. High throughput screening identifies novel lead compounds with activity against larval, juvenile and adult Schistosoma mansoni. PLoS Negl. Trop. Dis., 2016, 10(4), e0004659. doi: 10.1371/journal.pntd.0004659 PMID: 27128493
  13. McManus, D.P.; Dunne, D.W.; Sacko, M.; Utzinger, J.; Vennervald, B.J.; Zhou, X.N. Schistosomiasis. Nat. Rev. Dis. Primers, 2018, 4(1), 13. doi: 10.1038/s41572-018-0013-8 PMID: 30093684
  14. dos Santos Nascimento, I.J.; de Aquino, T.M.; da Silva-Júnior, E.F. Cruzain and rhodesain inhibitors: Last decade of advances in seeking for new compounds against American and African trypanosomiases. Curr. Top. Med. Chem., 2021, 21(21), 1871-1899. doi: 10.2174/18734294MTE10MTEoz PMID: 33797369
  15. Silva, L.R.; Guimarães, A.S.; do Nascimento, J.; do Santos Nascimento, I.J.; da Silva, E.B.; McKerrow, J.H.; Cardoso, S.H.; da Silva-Júnior, E.F. Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases. Bioorg. Med. Chem., 2021, 41, 116213. doi: 10.1016/j.bmc.2021.116213 PMID: 33992862
  16. Albino, S.L.; da Silva Moura, W.C.; Reis, M.M.L.; Sousa, G.L.S.; da Silva, P.R.; de Oliveira, M.G.C.; Borges, T.K.S.; Albuquerque, L.F.F.; de Almeida, S.M.V.; de Lima, M.C.A.; Kuckelhaus, S.A.S.; Nascimento, I.J.S.; Junior, F.J.B.M.; da Silva, T.G.; de Moura, R.O. ACW-02 an acridine triazolidine derivative presents antileishmanial activity mediated by dna interaction and immunomodulation. Pharmaceuticals, 2023, 16(2), 204. doi: 10.3390/ph16020204 PMID: 37259353
  17. Correnti, J.M.; Brindley, P.J.; Pearce, E.J. Long-term suppression of cathepsin B levels by RNA interference retards schistosome growth. Mol. Biochem. Parasitol., 2005, 143(2), 209-215. doi: 10.1016/j.molbiopara.2005.06.007 PMID: 16076506
  18. Jílková, A. Rubešová, P.; Fanfrlík, J.; Fajtová, P.; Řezáčová, P.; Brynda, J.; Lepšík, M.; Mertlíková-Kaiserová, H.; Emal, C.D.; Renslo, A.R.; Roush, W.R.; Horn, M.; Caffrey, C.R.; Mareš, M. Druggable hot spots in the schistosomiasis cathepsin B1 target identified by functional and binding mode analysis of potent vinyl sulfone inhibitors. ACS Infect. Dis., 2021, 7(5), 1077-1088. doi: 10.1021/acsinfecdis.0c00501 PMID: 33175511
  19. Sajid, M.; McKerrow, J.H.; Hansell, E.; Mathieu, M.A.; Lucas, K.D.; Hsieh, I.; Greenbaum, D.; Bogyo, M.; Salter, J.P.; Lim, K.C.; Franklin, C.; Kim, J.H.; Caffrey, C.R. Functional expression and characterization of Schistosoma mansoni cathepsin B and its trans-activation by an endogenous asparaginyl endopeptidase. Mol. Biochem. Parasitol., 2003, 131(1), 65-75. doi: 10.1016/S0166-6851(03)00194-4 PMID: 12967713
  20. Abdel Aziz, N.; Musaigwa, F.; Mosala, P.; Berkiks, I.; Brombacher, F. Type 2 immunity: A two-edged sword in schistosomiasis immunopathology. Trends Immunol., 2022, 43(8), 657-673. doi: 10.1016/j.it.2022.06.005 PMID: 35835714
  21. Li, Q.; Xu, J.; Li, S.Z.; Utzinger, J.; McManus, D.P.; Zhou, X.N. Short-, mid-, and long-term epidemiological and economic effects of the world bank loan project on schistosomiasis control in the people’s republic of China. Diseases, 2022, 10(4), 84. doi: 10.3390/diseases10040084 PMID: 36278583
  22. Schistosomiasis. Available from: https://www.who.int/news-room/fact-sheets/detail/schistosomiasis (Accessed on: Mar 6, 2023).
  23. Karunamoorthi, K.; Almalki, M.; Ghailan, K. Schistosomiasis: A neglected tropical disease of poverty: A call for intersectoral mitigation strategies for better health. J. Health Res. Rev., 2018, 5(1), 1. doi: 10.4103/jhrr.jhrr_92_17
  24. Lancelot, J.; Cabezas-Cruz, A.; Caby, S.; Marek, M.; Schultz, J.; Romier, C.; Sippl, W.; Jung, M.; Pierce, R.J. Schistosome sirtuins as drug targets. Future Med. Chem., 2015, 7(6), 765-782. doi: 10.4155/fmc.15.24 PMID: 25996069
  25. Barakat, R.M.R. Epidemiology of schistosomiasis in Egypt: Travel through time (Review). J. Adv. Res., 2013, 4(5), 425-432. doi: 10.1016/j.jare.2012.07.003 PMID: 25685449
  26. Tan, S.Y.; Ahana, A. Theodor Bilharz (1825-1862): Discoverer of schistosomiasis. Singapore Med. J., 2007, 48(3), 184-185. PMID: 17342284
  27. Wu, K.; Zhai, X.; Huang, S.; Jiang, L.; Yu, Z.; Huang, J. Protein kinases: Potential drug targets against schistosoma japonicum. Front. Cell. Infect. Microbiol., 2021, 11, 691757. doi: 10.3389/fcimb.2021.691757 PMID: 34277472
  28. Marker, E.; Debbert, S. Recent advances in anti-schistosomiasis drug discovery. In: Parasitic Helminths and Zoonoses - From Basic to Applied Research; IntechOpen, 2022. doi: 10.5772/intechopen.103056
  29. Xiao, S.H.; Sun, J.; Chen, M.G. Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: A scoping review of experimental studies. Infect. Dis. Poverty, 2018, 7(1), 9. doi: 10.1186/s40249-018-0391-x PMID: 29409536
  30. Friedman, J.F.; Olveda, R.M.; Mirochnick, M.H.; Bustinduy, A.L.; Elliott, A.M. Praziquantel for the treatment of schistosomiasis during human pregnancy. Bull. World Health Organ., 2018, 96(1), 59-65. doi: 10.2471/BLT.17.198879 PMID: 29403101
  31. Stothard, J.R.; Sousa-Figueiredo, J.C.; Navaratnam, A.M.D. Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis. Expert Rev. Anti Infect. Ther., 2013, 11(7), 733-752. doi: 10.1586/14787210.2013.811931 PMID: 23879611
  32. Knopp, S.; Becker, S.L.; Ingram, K.J.; Keiser, J.; Utzinger, J. Diagnosis and treatment of schistosomiasis in children in the era of intensified control. Expert Rev. Anti Infect. Ther., 2013, 11(11), 1237-1258. doi: 10.1586/14787210.2013.844066 PMID: 24127662
  33. Doenhoff, M.J.; Cioli, D.; Utzinger, J. Praziquantel: Mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis., 2008, 21(6), 659-667. doi: 10.1097/QCO.0b013e328318978f PMID: 18978535
  34. Bottieau, E.; Clerinx, J.; de Vega, M.R.; Van den Enden, E.; Colebunders, R.; Van Esbroeck, M.; Vervoort, T.; Van Gompel, A.; Van den Ende, J. Imported Katayama fever: Clinical and biological features at presentation and during treatment. J. Infect., 2006, 52(5), 339-345. doi: 10.1016/j.jinf.2005.07.022 PMID: 16169593
  35. Lambertucci, J.R.; Modha, J.; Curtis, R.; Doenhoff, M. The association of steroids and schistosomicides in the treatment of experimental schistosomiasis. Trans. R. Soc. Trop. Med. Hyg., 1989, 83(3), 354-357. doi: 10.1016/0035-9203(89)90502-6 PMID: 2515622
  36. Lambertucci, J.R. Acute schistosomiasis mansoni: Revisited and reconsidered. Mem. Inst. Oswaldo Cruz, 2010, 105(4), 422-435. doi: 10.1590/S0074-02762010000400012 PMID: 20721485
  37. El Guiniady, M.A.; Metwally, A.; Abdel-Bary, M.A.; Abdel-Fatah, S.A.; El Touny, M.A. Clinical and pharmacokinetic study of praziquantel in Egyptian Schistosomiasis patients with and without liver cell failure. Am. J. Trop. Med. Hyg., 1994, 51(6), 809-818. doi: 10.4269/ajtmh.1994.51.809 PMID: 7810816
  38. Mandour, M.E.M.; Turabi, H.E.; Homeida, M.M.A.; Sadig, T.; Ali, H.M.; Bennett, J.L.; Leahey, W.J.; Harron, D.W.G. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans. R. Soc. Trop. Med. Hyg., 1990, 84(3), 389-393. doi: 10.1016/0035-9203(90)90333-A PMID: 2124391
  39. Ortega-Pacheco, A.; Poot-Ramos, A.; Chan-Pérez, J.I.; Gutiérrez-Blanco, E.; Acevedo-Arcique, C.M.; Baak-Baak, C.M.; Jiménez-Coello, M. Evaluation of the effectiveness of fluralaner against adult stages of Rhodnius prolixus in dogs. Parasitol. Int., 2022, 87, 102508. doi: 10.1016/j.parint.2021.102508 PMID: 34781015
  40. Shuhua, X.; Binggui, S.; Chollet, J.; Utzinger, J.; Tanner, M. Tegumental alterations in juvenile Schistosoma haematobium harboured in hamsters following artemether treatment. Parasitol. Int., 2001, 50(3), 175-183. doi: 10.1016/S1383-5769(01)00076-9 PMID: 11595574
  41. Saeed, M.E.M.; Krishna, S.; Greten, H.J.; Kremsner, P.G.; Efferth, T. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol. Res., 2016, 110, 216-226. doi: 10.1016/j.phrs.2016.02.017 PMID: 26902577
  42. Shu-Hua, X. Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins. Acta Trop., 2005, 96(2-3), 153-167. doi: 10.1016/j.actatropica.2005.07.010 PMID: 16112072
  43. Njogu, P.M.; Okombo, J.; Chibale, K. Designed hybrid compounds for tropical parasitic diseases. In: Design of Hybrid Molecules for Drug Development; Elsevier, 2017; pp. 83-135. doi: 10.1016/B978-0-08-101011-2.00004-0
  44. Tripathi, T.; Chetri, P.B. Potent inhibitors of thioredoxin glutathione reductase: Grail of anti-schistosome drug within reach? ACS Infect. Dis., 2020, 6(5), 893-895. doi: 10.1021/acsinfecdis.0c00072 PMID: 32159329
  45. Song, L.; Li, J.; Xie, S.; Qian, C.; Wang, J.; Zhang, W.; Yin, X.; Hua, Z.; Yu, C. Thioredoxin glutathione reductase as a novel drug target: Evidence from Schistosoma japonicum. PLoS One, 2012, 7(2), e31456. doi: 10.1371/journal.pone.0031456 PMID: 22384025
  46. Kuntz, A.N.; Davioud-Charvet, E.; Sayed, A.A.; Califf, L.L.; Dessolin, J.; Arnér, E.S.J.; Williams, D.L. Thioredoxin glutathione reductase from Schistosoma mansoni: An essential parasite enzyme and a key drug target. PLoS Med., 2007, 4(6), e206. doi: 10.1371/journal.pmed.0040206 PMID: 17579510
  47. Prast-Nielsen, S.; Huang, H.H.; Williams, D.L. Thioredoxin glutathione reductase: Its role in redox biology and potential as a target for drugs against neglected diseases. Biochim. Biophys. Acta, Gen. Subj., 2011, 1810(12), 1262-1271. doi: 10.1016/j.bbagen.2011.06.024 PMID: 21782895
  48. Ghazy, E.; Abdelsalam, M.; Robaa, D.; Pierce, R.J.; Sippl, W. Histone deacetylase (HDAC) inhibitors for the treatment of schistosomiasis. Pharmaceuticals, 2022, 15(1), 80. doi: 10.3390/ph15010080 PMID: 35056137
  49. Fennell, B.J.; Naughton, J.A.; Barlow, J.; Brennan, G.; Fairweather, I.; Hoey, E.; McFerran, N.; Trudgett, A.; Bell, A. Microtubules as antiparasitic drug targets. Expert Opin. Drug Discov., 2008, 3(5), 501-518. doi: 10.1517/17460441.3.5.501 PMID: 23484923
  50. Chatterji, B.P.; Jindal, B.; Srivastava, S.; Panda, D. Microtubules as antifungal and antiparasitic drug targets. Expert Opin. Ther. Pat., 2011, 21(2), 167-186. doi: 10.1517/13543776.2011.545349 PMID: 21204724
  51. Monti, L.; Cornec, A.S.; Oukoloff, K.; Kovalevich, J.; Prijs, K.; Alle, T.; Brunden, K.R.; Smith, A.B., III; El-Sakkary, N.; Liu, L.J.; Syed, A.; Skinner, D.E.; Ballatore, C.; Caffrey, C.R. Congeners derived from microtubule-active phenylpyrimidines produce a potent and long-lasting paralysis of Schistosoma mansoni in vitro. ACS Infect. Dis., 2021, 7(5), 1089-1103. doi: 10.1021/acsinfecdis.0c00508 PMID: 33135408
  52. Oliveira, M.F.; d’Avila, J.C.P.; Torres, C.R.; Oliveira, P.L.; Tempone, A.J.; Rumjanek, F.D.; Braga, C.M.S.; Silva, J.R.; Dansa-Petretski, M.; Oliveira, M.A.; de Souza, W.; Ferreira, S.T. Haemozoin in Schistosoma mansoni. Mol. Biochem. Parasitol., 2000, 111(1), 217-221. doi: 10.1016/S0166-6851(00)00299-1 PMID: 11087932
  53. Xiao, S.; Sun, J. Schistosoma hemozoin and its possible roles. Int. J. Parasitol., 2017, 47(4), 171-183. doi: 10.1016/j.ijpara.2016.10.005 PMID: 28012717
  54. Corrêa Soares, J.B.R.; Menezes, D.; Vannier-Santos, M.A.; Ferreira-Pereira, A.; Almeida, G.T.; Venancio, T.M.; Verjovski-Almeida, S.; Zishiri, V.K.; Kuter, D.; Hunter, R.; Egan, T.J.; Oliveira, M.F. Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols. PLoS Negl. Trop. Dis., 2009, 3(7), e477. doi: 10.1371/journal.pntd.0000477 PMID: 19597543
  55. De Villiers, K.; Egan, T. Recent advances in the discovery of haem-targeting drugs for malaria and schistosomiasis. Molecules, 2009, 14(8), 2868-2887. doi: 10.3390/molecules14082868 PMID: 19701131
  56. Sun, J.; Li, C.; Wang, S. Organism-like formation of Schistosoma hemozoin and its function suggest a mechanism for anti-malarial action of artemisinin. Sci. Rep., 2016, 6(1), 34463. doi: 10.1038/srep34463 PMID: 27694940
  57. Okombo, J.; Singh, K.; Mayoka, G.; Ndubi, F.; Barnard, L.; Njogu, P.M.; Njoroge, M.; Gibhard, L.; Brunschwig, C.; Vargas, M.; Keiser, J.; Egan, T.J.; Chibale, K. Antischistosomal activity of pyrido1,2-abenzimidazole derivatives and correlation with inhibition of β-hematin formation. ACS Infect. Dis., 2017, 3(6), 411-420. doi: 10.1021/acsinfecdis.6b00205 PMID: 28440625
  58. Mayoka, G.; Keiser, J.; Häberli, C.; Chibale, K. Structure–activity relationship and in vitro absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies of N-aryl 3-trifluoromethyl pyrido1,2-abenzimidazoles that are efficacious in a mouse model of schistosomiasis. ACS Infect. Dis., 2019, 5(3), 418-429. doi: 10.1021/acsinfecdis.8b00313 PMID: 30580519
  59. Probst, A.; Chisanga, K.; Dziwornu, G.A.; Haeberli, C.; Keiser, J.; Chibale, K. Expanding the activity profile of pyrido1,2-abenzimidazoles: synthesis and evaluation of novel n1-1-phenylethanamine derivatives against Schistosoma mansoni. ACS Infect. Dis., 2021, 7(5), 1032-1043. doi: 10.1021/acsinfecdis.0c00278 PMID: 32786285
  60. Cruz, J.N.; Mali, S.N. Antimalarial hemozoin inhibitors (β-hematin formation inhibition): Latest updates. Comb. Chem. High Throughput Screen., 2022, 25(12), 1987-1990. doi: 10.2174/1386207325666220117145351 PMID: 35040394
  61. Mali, S.N.; Pandey, A. Hemozoin (beta-hematin) formation inhibitors: Promising target for the development of new antimalarials: Current update and future prospect. Comb. Chem. High Throughput Screen., 2022, 25(11), 1859-1874. doi: 10.2174/1386207325666210924104036 PMID: 34565319
  62. Mali, S.N.; Pandey, A. Synthesis, computational analysis, antimicrobial, antioxidant, trypan blue exclusion assay, β-hematin assay and anti-inflammatory studies of some hydrazones (Part-I); Curr. Comput. Aided Drug Des, 2022, p. 18.
  63. Patra, M.; Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.; Keiser, J.; Gasser, G. Ferrocenyl derivatives of the anthelmintic praziquantel: Design, synthesis, and biological evaluation. J. Med. Chem., 2012, 55(20), 8790-8798. doi: 10.1021/jm301077m PMID: 23005702
  64. Patra, M. Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.; Gasser, R.B.; Keiser, J.; Gasser, G. (η(6)-Praziquantel)Cr(CO)3 derivatives with remarkable in vitro anti-schistosomal activity. Chemistry, 2013, 19(7), 2232-2235. doi: 10.1002/chem.201204291 PMID: 23296750
  65. Patra, M.; Ingram, K.; Leonidova, A.; Pierroz, V.; Ferrari, S.; Robertson, M.N.; Todd, M.H.; Keiser, J.; Gasser, G. In vitro metabolic profile and in vivo antischistosomal activity studies of (η(6)-praziquantel)Cr(CO)3 derivatives. J. Med. Chem., 2013, 56(22), 9192-9198. doi: 10.1021/jm401287m PMID: 24219617
  66. Fonseca, N.C.; da Cruz, L.F.; da Silva Villela, F.; do Nascimento Pereira, G.A.; de Siqueira-Neto, J.L.; Kellar, D.; Suzuki, B.M.; Ray, D.; de Souza, T.B.; Alves, R.J.; Júnior, P.A.S.; Romanha, A.J.; Murta, S.M.F.; McKerrow, J.H.; Caffrey, C.R.; de Oliveira, R.B.; Ferreira, R.S. Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases rhodesain, cruzain, and Schistosoma mansoni cathepsin B1. Antimicrob. Agents Chemother., 2015, 59(5), 2666-2677. doi: 10.1128/AAC.04601-14 PMID: 25712353
  67. Jílková, A.; Řezáčová, P.; Lepšík, M.; Horn, M.; Váchová, J.; Fanfrlík, J.; Brynda, J.; McKerrow, J.H.; Caffrey, C.R.; Mareš, M. Structural basis for inhibition of cathepsin B drug target from the human blood fluke, Schistosoma mansoni. J. Biol. Chem., 2011, 286(41), 35770-35781. doi: 10.1074/jbc.M111.271304 PMID: 21832058
  68. Krautz-Peterson, G.; Skelly, P.J. Schistosome asparaginyl endopeptidase (legumain) is not essential for cathepsin B1 activation in vivo. Mol. Biochem. Parasitol., 2008, 159(1), 54-58. doi: 10.1016/j.molbiopara.2007.12.011 PMID: 18280591
  69. de Oliveira Fraga, L.A.; Lamb, E.W.; Moreno, E.C.; Chatterjee, M. Dvořák, J.; Delcroix, M.; Sajid, M.; Caffrey, C.R.; Davies, S.J. Rapid induction of IgE responses to a worm cysteine protease during murine pre-patent schistosome infection. BMC Immunol., 2010, 11(1), 56. doi: 10.1186/1471-2172-11-56 PMID: 21078176
  70. Tallima, H.; Abou El Dahab, M.; Kareem, S.; Dalton, J.P.; El Ridi, R. Protection against Schistosoma haematobium infection in hamsters by immunization with Schistosoma mansoni gut-derived cysteine peptidases, SmCB1 and SmCL3. Vaccine, 2017, 35(50), 6977-6983. doi: 10.1016/j.vaccine.2017.10.069 PMID: 29122387
  71. Jílková, A. Horn, M.; Fanfrlík, J.; Küppers, J.; Pachl, P.; Řezáčová, P.; Lepšík, M.; Fajtová, P.; Rubešová, P.; Chanová, M.; Caffrey, C.R.; Gütschow, M.; Mareš, M. Azanitrile inhibitors of the smcb1 protease target are lethal to Schistosoma mansoni: Structural and mechanistic insights into chemotype reactivity. ACS Infect. Dis., 2021, 7(1), 189-201. doi: 10.1021/acsinfecdis.0c00644 PMID: 33301315
  72. Jílková, A. Horn, M.; Řezáčová, P.; Marešová, L.; Fajtová, P.; Brynda, J.; Vondrášek, J.; McKerrow, J.H.; Caffrey, C.R.; Mareš, M. Activation route of the Schistosoma mansoni cathepsin B1 drug target: Structural map with a glycosaminoglycan switch. Structure, 2014, 22(12), 1786-1798. doi: 10.1016/j.str.2014.09.015 PMID: 25456815
  73. Ehmke, V.; Quinsaat, J.E.Q.; Rivera-Fuentes, P.; Heindl, C.; Freymond, C.; Rottmann, M.; Brun, R.; Schirmeister, T.; Diederich, F. Tuning and predicting biological affinity: Aryl nitriles as cysteine protease inhibitors. Org. Biomol. Chem., 2012, 10(30), 5764-5768. doi: 10.1039/c2ob00034b PMID: 22336919
  74. Yang, P.Y.; Wang, M.; Li, L.; Wu, H.; He, C.Y.; Yao, S.Q. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents. Chemistry, 2012, 18(21), 6528-6541. doi: 10.1002/chem.201103322 PMID: 22488888
  75. Ndao, M.; Beaulieu, C.; Black, W.C.; Isabel, E.; Vasquez-Camargo, F.; Nath-Chowdhury, M.; Massé, F.; Mellon, C.; Methot, N.; Nicoll-Griffith, D.A. Reversible cysteine protease inhibitors show promise for a Chagas disease cure. Antimicrob. Agents Chemother., 2014, 58(2), 1167-1178. doi: 10.1128/AAC.01855-13 PMID: 24323474
  76. Quesne, M.G.; Ward, R.A.; de Visser, S.P. Cysteine protease inhibition by nitrile-based inhibitors: A computational study. Front Chem., 2013, 1, 39. doi: 10.3389/fchem.2013.00039 PMID: 24790966
  77. Löser, R.; Frizler, M.; Schilling, K.; Gütschow, M. Azadipeptide nitriles: Highly potent and proteolytically stable inhibitors of papain-like cysteine proteases. Angew. Chem. Int. Ed., 2008, 47(23), 4331-4334. doi: 10.1002/anie.200705858 PMID: 18404765
  78. Frizler, M.; Lohr, F.; Lülsdorff, M.; Gütschow, M. Facing the gem-dialkyl effect in enzyme inhibitor design: Preparation of homocycloleucine-based azadipeptide nitriles. Chemistry, 2011, 17(41), 11419-11423. doi: 10.1002/chem.201101350 PMID: 21898616
  79. Laube, M.; Frizler, M.; Wodtke, R.; Neuber, C.; Belter, B.; Kniess, T.; Bachmann, M.; Gütschow, M.; Pietzsch, J.; Löser, R. Synthesis and preliminary radiopharmacological characterisation of an 11C‐labelled azadipeptide nitrile as potential PET tracer for imaging of cysteine cathepsins. J. Labelled Comp. Radiopharm., 2019, 62(8), 448-459. doi: 10.1002/jlcr.3729 PMID: 30912586
  80. Fanfrlík, J. Brahmkshatriya, P.S.; Řezáč J.; Jílková, A.; Horn, M.; Mareš, M.; Hobza, P.; Lepšík, M. Quantum mechanics-based scoring rationalizes the irreversible inactivation of parasitic Schistosoma mansoni cysteine peptidase by vinyl sulfone inhibitors. J. Phys. Chem. B, 2013, 117(48), 14973-14982. doi: 10.1021/jp409604n PMID: 24195769
  81. Palmer, J.T.; Rasnick, D.; Klaus, J.L.; Brömme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem., 1995, 38(17), 3193-3196. doi: 10.1021/jm00017a002 PMID: 7650671
  82. Brömme, D.; Klaus, J.L.; Okamoto, K.; Rasnick, D.; Palmer, J.T. Peptidyl vinyl sulphones: A new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem. J., 1996, 315(1), 85-89. doi: 10.1042/bj3150085 PMID: 8670136
  83. Barr, S.C.; Warner, K.L.; Kornreic, B.G.; Piscitelli, J.; Wolfe, A.; Benet, L.; McKerrow, J.H. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother., 2005, 49(12), 5160-5161. doi: 10.1128/AAC.49.12.5160-5161.2005 PMID: 16304193
  84. Abdulla, M.H.; Lim, K.C.; Sajid, M.; McKerrow, J.H.; Caffrey, C.R. Schistosomiasis mansoni: Novel chemotherapy using a cysteine protease inhibitor. PLoS Med., 2007, 4, 0130-0138.
  85. Roush, W.R.; Gwaltney, S.L., II; Cheng, J.; Scheidt, K.A.; McKerrow, J.H.; Hansell, E. Vinyl sulfonate esters and vinyl sulfonamides: Potent, irreversible inhibitors of cysteine proteases. J. Am. Chem. Soc., 1998, 120(42), 10994-10995. doi: 10.1021/ja981792o
  86. Scheidt, K.A.; Roush, W.R.; McKerrow, J.H.; Selzer, P.M.; Hansell, E.; Rosenthal, P.J. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorg. Med. Chem., 1998, 6(12), 2477-2494. doi: 10.1016/S0968-0896(98)80022-9 PMID: 9925304
  87. Somoza, J.R.; Zhan, H.; Bowman, K.K.; Yu, L.; Mortara, K.D.; Palmer, J.T.; Clark, J.M.; McGrath, M.E. Crystal structure of human cathepsin V. Biochemistry, 2000, 39(41), 12543-12551. doi: 10.1021/bi000951p PMID: 11027133
  88. Roush, W.R.; Cheng, J.; Knapp-Reed, B.; Alvarez-Hernandez, A.; McKerrow, J.H.; Hansell, E.; Engel, J.C. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorg. Med. Chem. Lett., 2001, 11(20), 2759-2762. doi: 10.1016/S0960-894X(01)00566-2 PMID: 11591518
  89. Chen, Y.T.; Brinen, L.S.; Kerr, I.D.; Hansell, E.; Doyle, P.S.; McKerrow, J.H.; Roush, W.R. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Negl. Trop. Dis., 2010, 4(9), e825. doi: 10.1371/journal.pntd.0000825 PMID: 20856868
  90. Brinen, L.S.; Hansell, E.; Cheng, J.; Roush, W.R.; McKerrow, J.H.; Fletterick, R.J. A target within the target: Probing cruzain’s P1′ site to define structural determinants for the Chagas’ disease protease. Structure, 2000, 8(8), 831-840. doi: 10.1016/S0969-2126(00)00173-8 PMID: 10997902
  91. Caffrey, C.R.; Hansell, E.; Lucas, K.D.; Brinen, L.S.; Alvarez Hernandez, A.; Cheng, J.; Gwaltney, S.L., II; Roush, W.R.; Stierhof, Y.D.; Bogyo, M.; Steverding, D.; McKerrow, J.H. Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol., 2001, 118(1), 61-73. doi: 10.1016/S0166-6851(01)00368-1 PMID: 11704274
  92. Ang, K.K.H.; Ratnam, J.; Gut, J.; Legac, J.; Hansell, E.; Mackey, Z.B.; Skrzypczynska, K.M.; Debnath, A.; Engel, J.C.; Rosenthal, P.J.; McKerrow, J.H.; Arkin, M.R.; Renslo, A.R. Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl. Trop. Dis., 2011, 5(5), e1023. doi: 10.1371/journal.pntd.0001023 PMID: 21572521
  93. Horn, M.; Jílková, A.; Vondrášek, J.; Marešová, L.; Caffrey, C.R.; Mareš, M. Mapping the pro-peptide of the Schistosoma mansoni cathepsin B1 drug target: Modulation of inhibition by heparin and design of mimetic inhibitors. ACS Chem. Biol., 2011, 6(6), 609-617. doi: 10.1021/cb100411v PMID: 21375333
  94. Chowdhury, S.F.; Sivaraman, J.; Wang, J.; Devanathan, G.; Lachance, P.; Qi, H.; Ménard, R.; Lefebvre, J.; Konishi, Y.; Cygler, M.; Sulea, T.; Purisima, E.O. Design of noncovalent inhibitors of human cathepsin L. from the 96-residue proregion to optimized tripeptides. J. Med. Chem., 2002, 45(24), 5321-5329. doi: 10.1021/jm020238t PMID: 12431059
  95. Choe, Y.; Leonetti, F.; Greenbaum, D.C.; Lecaille, F.; Bogyo, M.; Brömme, D.; Ellman, J.A.; Craik, C.S. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem., 2006, 281(18), 12824-12832. doi: 10.1074/jbc.M513331200 PMID: 16520377
  96. de Moraes, J. Antischistosomal natural compounds: Present challenges for new drug screens. In: Current Topics in Tropical Medicine; IntechOpen, 2012.
  97. Obe, A.F. Praziquantel: Do we need another antischistosoma treatment? Future Med. Chem., 2015, 7(6), 677-680. doi: 10.4155/fmc.15.16 PMID: 25996058
  98. Bergquist, R.; Utzinger, J.; Keiser, J. Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? Infect. Dis. Poverty, 2017, 6(1), 74. doi: 10.1186/s40249-017-0286-2 PMID: 28351414
  99. Tavares, N.C.; de Aguiar, P.H.N.; Gava, S.G.; Oliveira, G.; Mourão, M.M. Schistosomiasis: Setting Routes for Drug Discovery In: Special Topics in Drug Discovery; , 2016.
  100. Levecke, B.; Vlaminck, J.; Andriamaro, L.; Ame, S.; Belizario, V.; Degarege, A.; Engels, D.; Erko, B.; Garba, A.D.; Kaatano, G.M.; Mekonnen, Z.; Montresor, A.; Olliaro, P.; Pieri, O.S.; Sacko, M.; Sam-Wobo, S.O.; Tchuem Tchuenté, L.A.; Webster, J.P.; Vercruysse, J. Evaluation of the therapeutic efficacy of praziquantel against schistosomes in seven countries with ongoing large-scale deworming programs. Int. J. Parasitol. Drugs Drug Resist., 2020, 14, 183-187. doi: 10.1016/j.ijpddr.2020.10.003 PMID: 33125936
  101. Yu, Q.F.; Zhang, J.Y.; Sun, M.T.; Gu, M.M.; Zou, H.Y.; Webster, J.P.; Lu, D.B. In vivo praziquantel efficacy of Schistosoma japonicum over time: A systematic review and meta-analysis. Acta Trop., 2021, 222, 106048. doi: 10.1016/j.actatropica.2021.106048 PMID: 34273315
  102. Wang, W.; Wang, L.; Liang, Y.S. Susceptibility or resistance of praziquantel in human schistosomiasis: A review. Parasitol. Res., 2012, 111(5), 1871-1877. doi: 10.1007/s00436-012-3151-z PMID: 23052781
  103. Crellen, T.; Walker, M.; Lamberton, P.H.L.; Kabatereine, N.B.; Tukahebwa, E.M.; Cotton, J.A.; Webster, J.P. Reduced efficacy of praziquantel against schistosoma mansoni is associated with multiple rounds of mass drug administration. Clin. Infect. Dis., 2016, 63(9), 1151-1159. PMID: 27470241
  104. Lu, D.B.; Yu, Q.F.; Zhang, J.Y.; Sun, M.T.; Gu, M.M.; Webster, J.P.; Liang, Y.S. Extended survival and reproductive potential of single-sex male and female Schistosoma japonicum within definitive hosts. Int. J. Parasitol., 2021, 51(11), 887-891. doi: 10.1016/j.ijpara.2021.03.005 PMID: 33905765
  105. Fallon, P.G.; Doenhoff, M.J. Drug-resistant schistosomiasis: Resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg., 1994, 51(1), 83-88. doi: 10.4269/ajtmh.1994.51.83 PMID: 8059919
  106. Kwofie, S.K.; Agyenkwa-Mawuli, K.; Broni, E.; Miller, W.A., III; Wilson, M.D. Prediction of antischistosomal small molecules using machine learning in the era of big data. Mol. Divers., 2022, 26(3), 1597-1607. doi: 10.1007/s11030-021-10288-2 PMID: 34351547
  107. Cioli, D.; Pica-Mattoccia, L.; Basso, A.; Guidi, A. Schistosomiasis control: Praziquantel forever? Mol. Biochem. Parasitol., 2014, 195(1), 23-29. doi: 10.1016/j.molbiopara.2014.06.002 PMID: 24955523
  108. Gouveia, M.; Brindley, P.; Gärtner, F.; Costa, J.; Vale, N. Drug repurposing for schistosomiasis: Combinations of drugs or biomolecules. Pharmaceuticals, 2018, 11(1), 15. doi: 10.3390/ph11010015 PMID: 29401734
  109. Spangenberg, T. Alternatives to praziquantel for the prevention and control of schistosomiasis. ACS Infect. Dis., 2021, 7(5), 939-942. doi: 10.1021/acsinfecdis.0c00542 PMID: 32819092
  110. Pink, R.; Hudson, A.; Mouriès, M.A.; Bendig, M. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov., 2005, 4(9), 727-740. doi: 10.1038/nrd1824 PMID: 16138106
  111. Midzi, H.; Vengesai, A.; Muleya, V.; Kasambala, M.; Mduluza-Jokonya, T.L.; Chipako, I.; Siamayuwa, C.E.; Mutapi, F.M.; Naicker, T.; Mduluza, T. Metabolomics for biomarker discovery in schistosomiasis: A systematic scoping review. Front. Trop. Dis., 2023, 4, 1108317.
  112. Protasio, A.V.; Tsai, I.J.; Babbage, A.; Nichol, S.; Hunt, M.; Aslett, M.A.; De Silva, N.; Velarde, G.S.; Anderson, T.J.C.; Clark, R.C.; Davidson, C.; Dillon, G.P.; Holroyd, N.E.; LoVerde, P.T.; Lloyd, C.; McQuillan, J.; Oliveira, G.; Otto, T.D.; Parker-Manuel, S.J.; Quail, M.A.; Wilson, R.A.; Zerlotini, A.; Dunne, D.W.; Berriman, M. A systematically improved high quality genome and transcriptome of the human blood fluke Schistosoma mansoni. PLoS Negl. Trop. Dis., 2012, 6(1), e1455. doi: 10.1371/journal.pntd.0001455 PMID: 22253936
  113. Berriman, M.; Haas, B.J.; LoVerde, P.T.; Wilson, R.A.; Dillon, G.P.; Cerqueira, G.C.; Mashiyama, S.T.; Al-Lazikani, B.; Andrade, L.F.; Ashton, P.D.; Aslett, M.A.; Bartholomeu, D.C.; Blandin, G.; Caffrey, C.R.; Coghlan, A.; Coulson, R.; Day, T.A.; Delcher, A.; DeMarco, R.; Djikeng, A.; Eyre, T.; Gamble, J.A.; Ghedin, E.; Gu, Y.; Hertz-Fowler, C.; Hirai, H.; Hirai, Y.; Houston, R.; Ivens, A.; Johnston, D.A.; Lacerda, D.; Macedo, C.D.; McVeigh, P.; Ning, Z.; Oliveira, G.; Overington, J.P.; Parkhill, J.; Pertea, M.; Pierce, R.J.; Protasio, A.V.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Sajid, M.; Salzberg, S.L.; Stanke, M.; Tivey, A.R.; White, O.; Williams, D.L.; Wortman, J.; Wu, W.; Zamanian, M.; Zerlotini, A.; Fraser-Liggett, C.M.; Barrell, B.G.; El-Sayed, N.M. The genome of the blood fluke Schistosoma mansoni. Nature, 2009, 460(7253), 352-358. doi: 10.1038/nature08160 PMID: 19606141
  114. Luo, F.; Yin, M.; Mo, X.; Sun, C.; Wu, Q.; Zhu, B.; Xiang, M.; Wang, J.; Wang, Y.; Li, J.; Zhang, T.; Xu, B.; Zheng, H.; Feng, Z.; Hu, W. An improved genome assembly of the fluke Schistosoma japonicum. PLoS Negl. Trop. Dis., 2019, 13(8), e0007612. doi: 10.1371/journal.pntd.0007612 PMID: 31390359
  115. Young, N.D.; Jex, A.R.; Li, B.; Liu, S.; Yang, L.; Xiong, Z.; Li, Y.; Cantacessi, C.; Hall, R.S.; Xu, X.; Chen, F.; Wu, X.; Zerlotini, A.; Oliveira, G.; Hofmann, A.; Zhang, G.; Fang, X.; Kang, Y.; Campbell, B.E.; Loukas, A.; Ranganathan, S.; Rollinson, D.; Rinaldi, G.; Brindley, P.J.; Yang, H.; Wang, J.; Wang, J.; Gasser, R.B. Whole-genome sequence of Schistosoma haematobium. Nat. Genet., 2012, 44(2), 221-225. doi: 10.1038/ng.1065 PMID: 22246508
  116. Stroehlein, A.J.; Korhonen, P.K.; Chong, T.M.; Lim, Y.L.; Chan, K.G.; Webster, B.; Rollinson, D.; Brindley, P.J.; Gasser, R.B.; Young, N.D. High-quality Schistosoma haematobium genome achieved by single-molecule and long-range sequencing. Gigascience, 2019, 8(9), giz108. doi: 10.1093/gigascience/giz108 PMID: 31494670
  117. Mourão, M.M.; Grunau, C. LoVERDE, P.T.; Jones, M.K.; Oliveira, G. Recent advances in Schistosoma genomics. Parasite Immunol., 2012, 34(2-3), 151-162. doi: 10.1111/j.1365-3024.2011.01349.x PMID: 22145587
  118. LoVerde, P.T.; Hirai, H.; Merrick, J.M.; Lee, N.H.; El-Sayed, N. Schistosoma mansoni genome project: An update. Parasitol. Int., 2004, 53(2), 183-192. doi: 10.1016/j.parint.2004.01.009 PMID: 15081950
  119. Ferreira, L.G.; Oliva, G.; Andricopulo, A.D. Target-based molecular modeling strategies for schistosomiasis drug discovery. Future Med. Chem., 2015, 7(6), 753-764. doi: 10.4155/fmc.15.21 PMID: 25996068
  120. Simoens, S. Isabelle, H. R&D costs of new medicines: A landscape analysis. Front. Med., 2021, 8, 760762.
  121. Vemula, D.; Jayasurya, P.; Sushmitha, V.; Kumar, Y.N.; Bhandari, V. CADD, AI and ML in drug discovery: A comprehensive review. Eur. J. Pharm. Sci., 2023, 181, 106324. doi: 10.1016/j.ejps.2022.106324 PMID: 36347444
  122. Surabhi, S.; Singh, B.K. Computer aided drug design: An overview. J. Drug Deliv. Ther., 2018, 8(5), 504-509. doi: 10.22270/jddt.v8i5.1894
  123. Taboureau, O.; Baell, J.B.; Fernández-Recio, J.; Villoutreix, B.O. Established and emerging trends in computational drug discovery in the structural genomics era. Chem. Biol., 2012, 19(1), 29-41. doi: 10.1016/j.chembiol.2011.12.007 PMID: 22284352
  124. Mafud, A.C.; Ferreira, L.G.; Mascarenhas, Y.P.; Andricopulo, A.D.; de Moraes, J. Discovery of novel antischistosomal agents by molecular modeling approaches. Trends Parasitol., 2016, 32(11), 874-886. doi: 10.1016/j.pt.2016.08.002 PMID: 27593339

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bentham Science Publishers, 2024